rhuMAb-VEGF: Phase II

Interim data from an ongoing open label study in 59 women with relapsed metastatic breast cancer showed objective responses in 5 women given rhuMAb-VEGF alone, 1 in the 3 mg/kg arm and 4 in the 10 mg/...